Related Experiment Videos
[Hematologic aspects of inflammatory bowel diseases]
M Udvardy1, I Altorjay, K Palatka
1Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, II. Belgyógyászati Klinika.
Orvosi Hetilap
|May 26, 2001
Summary
Hematologic changes like anemia and thrombocytosis are common in inflammatory bowel disease (IBD). This review explores the links between hematology and IBD, including thrombosis risks and potential therapeutic targets.
Area of Science:
- Hematology
- Gastroenterology
- Thrombosis
Context:
- Inflammatory bowel disease (IBD) is frequently associated with secondary hematologic alterations.
- Anemia and thrombocytosis are common indicators of IBD severity.
- IBD patients exhibit altered platelet function, coagulation, and fibrinolysis, increasing thromboembolic risk.
Purpose:
- To review the intricate relationship between hematologic abnormalities and inflammatory bowel disease.
- To discuss the role of hematologic factors in IBD pathogenesis and clinical course.
- To highlight potential therapeutic implications of hematologic findings in IBD.
Summary:
- Hematologic changes, including anemia and thrombocytosis, are prevalent in IBD and correlate with disease severity.
- Increased platelet activity, hypercoagulability, and fibrinolytic defects in IBD patients contribute to thromboembolic events and microcirculatory disturbances.
- Reduced Factor XIII (FXIII) levels in IBD may impact mucosal healing and offer therapeutic potential, while the prevalence and significance of genetic thrombophilia in IBD require further investigation.
Impact:
- Understanding these hematologic links can improve the management of IBD patients.
- Identifying specific hematologic markers may aid in predicting IBD progression and treatment response.
- Further research into hematologic factors could unveil novel therapeutic strategies for IBD.